Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Biohaven Pharmaceutical Holding Company Ltd
BHVN | US
9.88
USD-0.64
-6.08%
BHVN | US
Loading StockChartView...
About Biohaven Pharmaceutical Holding Company Ltd
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
9.88
Open
10.56
High
10.56
Low
9.83
Biohaven Ltd. a clinical-stage biopharmaceutical company focuses on discovering developing and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000 a potassium channel activator for the treatment of focal epilepsy; BHV-7010 a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat an oral myeloperoxidase inhibitor which is in Phase 3 clinical trial for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa an anti-myostatin adnectin which is in Phase 3 clinical trial for the treatment of spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.
View LessBHVN | US
Risk
87.6
Sharpe
-0.64
Luna's Score
42/100
Recommendation
Sell
Luna says (BHVN | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
What's not Working
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
90.3%1 month
87.6%3 months
69.3%6 months
99.2%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
13.93
Debt to equity
0.08
Debt to assets
0.05
Ent. to EBITDA
-2.19
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-774.44M
MarketCap
997.41M
MarketCap(USD)
997.41M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-193.67
Short ratio
7.11
Short perc.
10.71
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
2.02
Range1M
3.03
Range3M
5.98
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.82
Price X volume
15.25M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -2.19 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 13.93 | 15.55 | Par |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 69.30 | 72.80 | Par |
| Debt to Equity | 0.08 | -1.23 | Expensive |
| Debt to Assets | 0.05 | 0.25 | Cheaper |
| Market Cap | 997.41M | 3.66B | Emerging |
